RSS

Shire

Following a dip in the first-quarter operating profit announced by Takeda, which is being attributed to the loss of US exclusivity for its blockbuster cancer drug and a lacking pipeline, it may find a saving grace in its recent merger with Shire more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Global biotechnology company, Shire, has received approval from the US Food and Drug Administration (FDA) for its first submission of its new plasma manufacturing facility near Covington, Georgia, where Gammagard Liquid will be produced. more

News

Shire has announced that the European Medicines Agency (EMA) has validated its marketing authorisation application (MAA) for lanadelumab (SHP643) for investigational Hereditary Angioedema (HAE) treatment. more

News

Biotechnology company, Shire, has announced a professional training development collaboration with the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

Global biotechnology company, Shire, has filed its first submission to the US Food and Drug Administration (FDA) for a new plasma manufacturing facility in Covington, Georgia, to support growth in its immunology franchise. more

News

Biotech company, Shire, has been granted fast track designation by the US Food and Drug Administration (FDA) for SHP607, which is indicated for the prevention of chronic lung disease in extremely premature infants. more

News

Global biotechnology company, Shire, has submitted a marketing authorisation application (MAA) for its dry eye treatment, liftegrast, which, if approved, would represent the first and only LFA-1 antagonist drug to treat the disease in Europe. more

News

Abbvie, Sanofi and Novo Nordisk seens as most reputable pharma companies in the UK and industry as a whole ranked third most reputable by general public more

News

UK-based Shire and Baxalta have announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta more

News

Shire is to acquire all outstanding shares of NPS Pharmaceuticals for $46.00 per share in cash, for a total consideration of approximately $5.2 billion. more

News